Malaysian Biotech Licenses Technology For Non-Cancer Therapy (Malaysia)
This article was originally published in PharmAsia News
Malaysia's Biotechnology Corp. says it has made its first technology licensing agreement, with the French start-up Nanobiotix. The cost of the deal was not disclosed. Nanobiotix makes nanotechnology applications for cancer therapy. Biotech intends to license the nanotechnology for purposes other than cancer, the firm's current primary focus. Nanobiotix CEO Laurent Levy said the agreement would allow it to expand its pipeline into non-cancer areas. (Click here for more
You may also be interested in...
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.